نتایج جستجو برای: imiquimod

تعداد نتایج: 1595  

Journal: :Journal of lower genital tract disease 2014
Claudia Marchitelli Maria Sol Peremateu Maria Celeste Sluga Maria Teresa Berasategui Delia Graciela Lopez Alejandra Wernicke Andrea Velazco Sebastian Gogorza

INTRODUCTION Our objective was to evaluate the efficacy of conservative treatment with imiquimod in Paget vulvar disease. MATERIALS AND METHODS We describe a case series that includes 10 patients with histopathologic diagnosis of extramammary Paget disease of the vulva, who were treated with 5% imiquimod cream. Of these patients, 3 were treated for recurrent disease and 7 were treated for ini...

Journal: :Archives of dermatology 2007
Carlos Garcia Eduardo Poletti

superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-733. 7. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehiclecontrolled phase III study in Europe. Br J Dermatol. 2005;152:939-947. 8. Sterry W, Ruzicka T, Herrera E, e...

Journal: :Cancer research 1993
P L Witt P S Ritch D Reding T L McAuliffe L Westrick S E Grossberg E C Borden

Imiquimod [1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine] is a compound of low molecular weight that, when administered p.o., induces interferon-alpha in several animal species and inhibits tumor growth in mice. To determine maximum tolerated dose, toxicity, and biological response in humans, a phase I clinical trial was conducted with 14 eligible cancer patients who received 100-500 mg i...

2016
Xing-hua Gao

Objective: To assess the efficacy and safety of imiquimod for treating verruca planae. Methods: We searched the Pubmed, Cochrane Register of Controlled Trials, EMbase, CBM, CNKI and Wanfang databases (Chinese) to collect randomized controlled trials (RCTs). We screened the retrieved studies according to the predefined inclusion and exclusion criteria, evaluated the quality of include studies, a...

Journal: :Journal of Investigative Dermatology 2004

2013
Rym Benmously-Mlika Wafa Koubaa Achraf Debbiche Insaf Mokhtar

not available in our country, and surgery, in which recurrence rates after wide excision are lower than after local excision. Radiotherapy has been used only rarely for BD of the digit and has been delivered using various techniques (radioactive molds of gold or radon seeds, external beam therapy, photon radiotherapy using a water bath), as have laser carbon dioxide, photodynamic therapy, and t...

Journal: :The British journal of dermatology 2003
M F Naylor N Crowson R Kuwahara K Teague C Garcia C Mackinnis R Haque C Odom C Jankey R L Cornelison

A published case report and anecdotal experience suggested that topical imiquimod is an effective treatment for stage 0 melanoma (lentigo maligna). To gauge the efficacy of this therapy, we undertook a trial of topical imiquimod in 30 subjects with histologically confirmed lentigo maligna. Thirty subjects with lentigo maligna were recruited for an open-labelled efficacy trial with daily topical...

2012
Simone M Goldinger Reinhard Dummer Petra Baumgaertner Daniela Mihic-Probst Katrin Schwarz Anya Hammann-Haenni Joerg Willers Christine Geldhof John O Prior Thomas M Kündig Olivier Michielin Martin F Bachmann Daniel E Speiser

Optimal vaccine strategies must be identified for improving T-cell vaccination against infectious and malignant diseases. MelQbG10 is a virus-like nano-particle loaded with A-type CpG-oligonucleotides (CpG-ODN) and coupled to peptide(16-35) derived from Melan-A/MART-1. In this phase IIa clinical study, four groups of stage III-IV melanoma patients were vaccinated with MelQbG10, given (i) with ...

Journal: :Vaccine 2010
Anna H Roukens Ann C Vossen Greet J Boland Willem Verduyn Jaap T van Dissel Leo G Visser

BACKGROUND Five to ten percent of immunocompetent persons fail to develop a protective immune response to hepatitis B vaccination, and are defined non-responders (NR). We investigated the immune response to intradermal hepatitis B vaccination after pre-treatment of the skin with the TLR7 agonist imiquimod. METHODS Twenty-one non-responders (anti-HBs <10 IU/l after at least 6 intramuscular hep...

Journal: :Acta dermato-venereologica 2005
Jens-Michael Jensen Friederike Egberts Ehrhardt Proksch Axel Hauschild

Sir, Disseminated porokeratosis palmaris and plantaris (DPPP), a subtype of porokeratosis Mibelli, is a rare autosomal dominant genodermatosis first described by Guss et al. in 1971 (1). An early review of the literature showed that 7% of 250 patients with porokeratosis subsequently developed skin tumours (2). Squamous cell carcinomas (SCC), Bowen’s disease (BD), and rarely, basal cell carcinom...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید